Avadel Pharmaceuticals PLC AVDL
Institutional shares held
68.4 Million
1.01M
calls
2.03M
puts
Total value of holdings
$1.08B
$15.9M
calls
$32M
puts
Market Cap
$954M
60,581,300
Shares Out.
Institutional ownership
112.91%
# of Institutions
133
We take great care to ensure that the data presented and summarized in this overview for AVADEL PHARMACEUTICALS PLC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding AVDL
View all-
Janus Henderson Group PLC London, X012.9MShares$203 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY8.8MShares$139 Million2.38% of portfolio
-
Polar Capital Holdings PLC London, X06.75MShares$106 Million0.71% of portfolio
-
Gendell Jeffrey L Greenwich, CT5.71MShares$89.9 Million3.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA3.97MShares$62.6 Million8.97% of portfolio
-
Braidwell LP Stamford, CT2.67MShares$42 Million1.45% of portfolio
-
Wealth Effects LLC2.26MShares$35.7 Million14.2% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA1.91MShares$30.1 Million0.06% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny1.81MShares$28.5 Million0.01% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il1.56MShares$24.6 Million0.01% of portfolio
Latest Institutional Activity in AVDL
Top Purchases
Top Sells
About AVDL
Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.
Insider Transactions at AVDL
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 16
2024
|
Thomas S Mchugh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+2.42%
|
$28,000
$14.5 P/Share
|
|
Dec 28
2023
|
Mark Anthony Mc Camish Director |
SELL
Open market or private sale
|
Indirect |
75,000
-52.81%
|
$1,050,000
$14.53 P/Share
|
|
Aug 14
2023
|
Thomas S Mchugh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,000
+2.48%
|
$28,000
$14.45 P/Share
|
|
Aug 11
2023
|
Mark Anthony Mc Camish Director |
SELL
Open market or private sale
|
Indirect |
28,975
-16.94%
|
$405,650
$14.93 P/Share
|
|
Aug 10
2023
|
Geoffrey Michael Glass Director |
BUY
Open market or private purchase
|
Indirect |
14,000
+19.18%
|
$182,000
$13.4 P/Share
|
|
Aug 10
2023
|
Gregory J Divis Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+5.91%
|
$130,000
$13.2 P/Share
|
|
May 18
2023
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
13,000
+7.19%
|
$169,000
$13.93 P/Share
|
|
May 09
2023
|
Linda Palczuk Director |
BUY
Open market or private purchase
|
Direct |
2,500
+4.55%
|
$35,000
$14.76 P/Share
|
|
Dec 23
2022
|
Linda Palczuk Director |
BUY
Open market or private purchase
|
Direct |
2,000
+3.85%
|
$14,000
$7.2 P/Share
|
|
Nov 29
2022
|
Thomas S Mchugh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
5,000
+6.14%
|
$35,000
$7.8 P/Share
|
|
Nov 22
2022
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
20,000
+11.44%
|
$140,000
$7.8 P/Share
|
|
Jun 01
2022
|
Geoffrey Michael Glass Director |
BUY
Open market or private purchase
|
Indirect |
45,000
+50.0%
|
$90,000
$2.14 P/Share
|
|
Jun 01
2022
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
20,000
+12.91%
|
$40,000
$2.27 P/Share
|
|
May 31
2022
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
15,000
+11.55%
|
$30,000
$2.16 P/Share
|
|
May 27
2022
|
Peter J. Thornton Director |
BUY
Open market or private purchase
|
Direct |
50,000
+37.58%
|
$50,000
$1.69 P/Share
|
|
May 27
2022
|
Gregory J Divis Chief Executive Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+25.11%
|
$100,000
$2.05 P/Share
|
|
May 27
2022
|
Eric J Ende Director |
BUY
Open market or private purchase
|
Direct |
15,000
+13.05%
|
$30,000
$2.45 P/Share
|
|
May 27
2022
|
Thomas S Mchugh Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
50,000
+41.15%
|
$100,000
$2.14 P/Share
|
|
May 27
2022
|
Linda Palczuk Director |
BUY
Open market or private purchase
|
Direct |
10,000
+17.27%
|
$10,000
$1.6 P/Share
|
|
Dec 21
2020
|
Geoffrey Michael Glass Director |
SELL
Bona fide gift
|
Direct |
18,600
-28.31%
|
-
|
Last 12 Months Summary
Buy / Acquisition
28K
Shares
From
3
Insiders
| Open market or private purchase | 28K shares |
|---|
Sell / Disposition
104K
Shares
From
1
Insiders
| Open market or private sale | 104K shares |
|---|